FDA gives Saniona candidate priority status

The US Food and Drug Administration FDA has given orphan drug priority status to Saniona's drug candidate Tesomet for treating hypothalamic obesity (HO), according to a press release on Monday.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Saniona borrows USD 10m for clinical studies
For subscribers